Effect of 5-Ht1 agonist (sumatriptan) on anorectal function in irritable bowel syndrome patients

World Journal of Gastroenterology

Volumn 12, Issue 10, 2006, Pages 1591-1596

  Mulak, Agata ^a   Paradowski, Leszek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

5 HT receptors; Anorectal function; Irritable bowel syndrome; Sumatriptan

Indexed keywords

PLACEBO; SEROTONIN 1 AGONIST; SEROTONIN 1 RECEPTOR; SUMATRIPTAN SUCCINATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ANORECTAL PRESSURE; ANUS SPHINCTER; ARTICLE; BALLOON DILATATION; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEFECATION URGENCY; DISEASE CLASSIFICATION; DROWSINESS; DYSPNEA; FEMALE; FORMICATION; HEADACHE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; MALE; MUSCLE WEAKNESS; NAUSEA; NOSE DISEASE; PARESTHESIA; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THORAX PAIN; THROAT DISEASE; TREATMENT OUTCOME;

EID: 33645729806     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i10.1591     Document Type: Article

References (24)

1. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-2709
2. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004; 141: 1285-1293
3. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 Suppl 7: 3-14
4. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068
5. Mulak A, Paradowski L. Therapy for irritable bowel syndrome - present possibilities and new perspectives. Gastroenterologia Polska 2004; 11: 521-527
6. Baker DE. Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 2005; 62: 700-711; quiz 712-713
7. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-332
8. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122:1140-1156
9. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-473
10. Malatesta MG, Fascetti E, Ciccaglione AF, Cappello G, Grossi L, Ferri A, Marzio L. 5-HT1-receptor agonist sumatriptan modifies gastric size after 500 ml of water in dyspeptic patients and normal subjects. Dig Dis Sci 2002; 47: 2591-2595
11. Tohgi H, Abe T, Takahashi S, Ueno M, Nozaki Y. Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms. Adv Neurol 1990; 53: 277-282
12. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777
13. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471-474
14. Simren M, Abrahamsson H, Bjornsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-27
15. Caldarella MP, Milano A, Laterza F, Sacco F, Balatsinou C, Lapenna D, Pierdomenico SD, Cuccurullo F, Neri M. Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion. Am J Gastroenterol 2005; 100: 383-389
16. Grossi L, Ciccaglione AF, Marzio L. Effect of the 5-HT1 agonist sumatriptan on oesophageal motor pattern in patients with ineffective oesophageal motility. Neurogastroenterol Motil 2003; 15:9-14
17. Sarnelli G, Janssens J, Tack J. Effect of intranasal sumatriptan on gastric tone and sensitivity to distension. Dig Dis Sci 2001; 46:1591-1595
18. Neri M, Marzio L, DeAngelis C, Pieramico O, Mezzetti A, Cuccurullo F. Effect of ketanserin, a selective antiserotoninergic drug, on human anal canal pressure. Int J Colorectal Dis 1988; 3: 219-221
19. Enck P, Arping HG, Engel S, Bielefeldt K, Erckenbrecht JF. Effects of cisapride on ano-recta sphincter function. Aliment Pharmacol Ther 1989; 3: 539-545
20. Sloots CE, Poen AC, Kerstens R, Stevens M, De Pauw M, Van Oene JC, Meuwissen SG, Felt-Bersma RJ. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-767
21. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-585
22. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 869-878
23. Siproudhis L, Dinasquet M, Sebille V, Reymann JM, Bellissant E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. Aliment Pharmacol Ther 2004; 20: 689-695
24. Mulak A, Bonaz B. Irritable bowel syndrome: a model of the brain-gut interactions. Med Sci Monit 2004; 10: RA55-RA62